PT - JOURNAL ARTICLE AU - Alexis Ogdie AU - Mei Liu AU - Meghan Glynn AU - Kelechi Emeanuru AU - Leslie Harrold AU - Sven Richter AU - Benoit Guerette AU - Philip J. Mease TI - Descriptive Comparisons of the Impact of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: the Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results AID - 10.3899/jrheum.191209 DP - 2020 Nov 15 TA - The Journal of Rheumatology PG - jrheum.191209 4099 - http://www.jrheum.org/content/early/2020/11/10/jrheum.191209.short 4100 - http://www.jrheum.org/content/early/2020/11/10/jrheum.191209.full AB - Objective Therapeutic response was evaluated among new apremilast, methotrexate, or biologic disease-modifying anti-rheumatic drug (bDMARD) initiators with oligoarticular psoriatic arthritis (PsA). Methods Patients with oligoarticular PsA in the Corrona PsA/Spondyloarthritis Registry initiating treatment with apremilast, methotrexate, or bDMARD and completing 6-month follow-up were included. Results In total, 150 patients initiated monotherapy (apremilast: n=34; methotrexate: n=15; bDMARD: n=101). Apremilast initiators had higher baseline disease activity than methotrexate initiators. At follow-up, apremilast initiators experienced numerically greater disease activity improvements than methotrexate initiators and similar improvements to bDMARD initiators. Conclusion Findings suggest apremilast monotherapy is an effective option for patients with oligoarticular PsA.